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Introduction {#ehf212207-sec-0004}
============

In apparently healthy subjects and in patients with suspected cardiac disease, self‐reported exercise‐induced dyspnoea has been shown to identify a subgroup of subjects at higher risk of cardiovascular death in several[1](#ehf212207-bib-0001){ref-type="ref"}, [2](#ehf212207-bib-0002){ref-type="ref"}, [3](#ehf212207-bib-0003){ref-type="ref"}---albeit not all---reports.[4](#ehf212207-bib-0004){ref-type="ref"} Muscular fatigue and dyspnoea are the two main symptoms that are referred by chronic heart failure (HF) patients as the cause of exercise limitation. However, the role of dyspnoea at peak exercise as associated with prognosis is presently unclear in this setting, as only few studies have evaluated this issue, and with contradictory results. Indeed, in a report by Chase *et al*.,[5](#ehf212207-bib-0005){ref-type="ref"} exercise dyspnoea has been linked to a poorer exercise performance and a higher risk of adverse cardiovascular events, while in the series of HF patients of Witte *et al*.,[6](#ehf212207-bib-0006){ref-type="ref"} no differences in peak VO~2~ and prognosis were observed when comparing patients with and without dyspnoea as exercise limiting symptom.

The cause of exercise‐induced dyspnoea in HF patients has also been studied, but a clear physiological explanation is not available. In their pioneering work, Wilson and Mancini[7](#ehf212207-bib-0007){ref-type="ref"} suggested that exercise dyspnoea in HF is due to increased respiratory muscle work mediated by excessive ventilation and decreased lung compliance. Moreover, Nanas *et al*.[8](#ehf212207-bib-0008){ref-type="ref"} reported a correlation between inspiratory capacity and wedge pressure, and both were associated with exercise performance. Differently, Russel *et al*.[9](#ehf212207-bib-0009){ref-type="ref"} were unable to show a correlation between dyspnoea and lung function at rest and during exercise in HF patients. According to the study by Nanas *et al*.,[8](#ehf212207-bib-0008){ref-type="ref"} we observed a strong correlation between pulmonary function and exercise performance and, after a therapeutic intervention, an improvement of both pulmonary function and exercise performance, but not of alveolar capillary membrane gas diffusion.[10](#ehf212207-bib-0010){ref-type="ref"}, [11](#ehf212207-bib-0011){ref-type="ref"}, [12](#ehf212207-bib-0012){ref-type="ref"}, [13](#ehf212207-bib-0013){ref-type="ref"} However, in all these studies,[8](#ehf212207-bib-0008){ref-type="ref"}, [10](#ehf212207-bib-0010){ref-type="ref"}, [11](#ehf212207-bib-0011){ref-type="ref"}, [12](#ehf212207-bib-0012){ref-type="ref"} no correlation was reported between lung function abnormalities and exercise dyspnoea. So even at present, the reason why some HF patients end their exercise performance because of dyspnoea and other because of fatigue is basically unknown.[14](#ehf212207-bib-0014){ref-type="ref"} Accordingly, we analysed whether patients referring dyspnoea or fatigue as the cause of exercise limitation are characterized by a different ventilatory or haemodynamic behaviour during exercise. Specifically, we studied the behaviour of exercise performance, ventilatory pattern, and cardiac output (CO) in 170 consecutive HF patients who performed a maximal standard cardiopulmonary exercise testing (CPET) and a second maximal CPET to measure CO (CPET‐CO) at rest and at peak exercise by inert gas rebreathing (IGR).

Methods {#ehf212207-sec-0005}
=======

Patient population {#ehf212207-sec-0006}
------------------

We retrospectively analysed the clinical data, obtained as part of the routine HF follow‐up program, of 170 consecutive patients (146 men and 24 women) who underwent full clinical evaluation at our HF unit. All patients underwent both CPET and CPET‐CO within 2 months (16 ± 15 days). Patients belong to a cohort of HF patients regularly followed up at our HF unit. All were in stable clinical condition, in New York Heart Association (NYHA) functional class I--III, capable of performing standard CPET and rebreathing manoeuvres.

We excluded from data analysis HF patients with preserved left ventricular ejection fraction (LVEF) (\>50% at echocardiography), and patients with primary pulmonary hypertension and pulmonary embolism or any disease, which per se influenced their exercise capacity.

Heart failure aetiology was as follows: ischaemic heart disease (35 patients), idiopathic cardiomyopathy (114 patients) and valvular heart disease (21 patients).

For the present analysis, we evaluated NYHA class, resting haemoglobin, brain natriuretic peptide, conventional two‐dimensional and Doppler echocardiography, standard spirometry, CPET, and CPET‐CO. Spirometry was performed according to current guidelines with a mass flow‐meter (SensorMedics, Yorba Linda, CA, USA).[15](#ehf212207-bib-0015){ref-type="ref"} Predicted values were calculated according to Quanjer *et al*.[16](#ehf212207-bib-0016){ref-type="ref"}

Cardiopulmonary exercise testing {#ehf212207-sec-0007}
--------------------------------

A maximal CPET was performed (229D Spectra metabolic cart, SensorMedics) on a cycle ergometer in patients without contraindications to the test (Erg 800S, SensorMedics), using a personalized ramp protocol aimed at achieving peak exercise in around 10 min. The majority of these patients had previously undergone a CPET in our laboratory; the other patients underwent a familiarization procedure. We analysed CPET using a standard methodology. All CPETs were performed by a cardiology expert on CPET, a fellow, and a dedicated nurse. CPET was self‐interrupted by the patients when he or she claimed that he or she had reached a maximal effort. We systematically asked the patients the reason why the procedure was terminated and if it was specifically because of chest pain, dyspnoea, or fatigue. Peak VO~2~ was calculated as an average over 30 s and reported either as absolute value or as a percentage of the VO~2~ max predicted value.[17](#ehf212207-bib-0017){ref-type="ref"} The O~2~ pulse was calculated as VO~2~/heart rate (HR). The VO~2~/work relationship was calculated through the entire exercise, while the ventilation (VE)/carbon dioxide flow (VCO~2~) slope was calculated as the slope of the relationship between VE and VCO~2~ from approximately 1 min after the beginning of loaded exercise to the end of the isocapnic buffering period.[18](#ehf212207-bib-0018){ref-type="ref"}

A CPET‐CO was performed using the same ramp protocol of CPET. CO was measured at rest and at peak exercise using an IGR method[19](#ehf212207-bib-0019){ref-type="ref"}, [20](#ehf212207-bib-0020){ref-type="ref"}, [21](#ehf212207-bib-0021){ref-type="ref"} that required a few teaching sessions to familiarize patients with the necessary manoeuvre. The IGR technique has been previously reported in detail.[19](#ehf212207-bib-0019){ref-type="ref"} In brief, the IGR technique uses an oxygen‐enriched mixture of an inert soluble gas (0.5% nitrous oxide) and an inert insoluble gas (0.1% sulfur hexafluoride) inflated into a bag by the machine. Patients have to breathe into a respiratory valve via a mouthpiece and a bacterial filter with a nose clip. At the end of expiration, the valve is activated automatically so that patients rebreathe from the prefilled bag for a period of 10 to 20 s. After that period, patients start breathing ambient air again. CO measurement is performed by a photo‐acoustic analyser that measures gas concentration over a five‐breath interval. Sulfur hexafluoride, which is insoluble in blood, is used to determine lung volume, while the concentration of nitrous oxide, which is soluble in blood, decreases during rebreathing with a rate that is proportional to pulmonary blood flow. CO is equal to pulmonary blood flow only if the arterial oxygen saturation (SpO~2~) measure is \>98% at pulse oximeter, showing the absence of pulmonary shunt flow. If SpO~2~ is \<98%, CO is equal to pulmonary blood flow plus shunt flow.[19](#ehf212207-bib-0019){ref-type="ref"} In CPET‐CO, respiratory gases and ventilation were measured breath by breath as in CPET.

Arterio‐venous O~2~ content differences \[ΔCO~2~(a‐v)\] was calculated as VO~2~/CO.

Both CPETs were performed as part of the clinical evaluation that we routinely perform at our HF unit. We obtained written informed consent before each CPET for the exercise procedure as well as for the blind research use of CPET derived data as well as for all patients\' clinical data. The present retrospective study was reviewed and approved by our institutional review board (Centro Cardiologico Monzino ethics committee) before the study began.

Statistical analysis {#ehf212207-sec-0008}
--------------------

Continuous variables were expressed as means ± standard deviation, or as median and interquartile range if not normally distributed. Comparisons between the two groups were performed using unpaired *t*‐tests for normally distributed variables, and Mann--Whitney *U*‐test for non‐normally distributed variables. *P* \< 0.05 was considered statistically significant.

Statistical analysis was performed using [spss]{.smallcaps} 23.0 software (SPSS Inc., Chicago, IL, USA).

Results {#ehf212207-sec-0009}
=======

We studied a cohort of 170 patients in NYHA class I, *n* = 42 (25%); II, *n* = 93 (55%); and III, *n* = 35 (20%). Patients\' age was 65 ± 11 years, and 86% were male. Average LVEF was 31 ± 8%. Spirometry showed forced expiratory volume in 1 s is equal to 82.8 ± 18.0% of the predicted value and forced vital capacity equal to 88.2 ± 16.9% of the predicted value. Thirty‐eight patients terminated the CPET procedure because of dyspnoea, and 132 because of muscular fatigue. The mean ramp protocol used was 9.03 ± 3.3 W/min in both exercise tests. The duration of the tests was 9.3 ± 1.7 and 9.1 ± 2.7 min (average work rate = 83.4 ± 33.4 W) in CPET and CPET‐CO, respectively. Peak exercise respiratory gas exchange was 1.14 ± 0.11 in CPET, showing that, on average, patients performed a maximal or nearly maximal exercise test in both CPETs.

The cardiorespiratory performance was analysed during CPET to avoid any possible interference of the rebreathing manoeuvre with ventilation and respiratory gases. The anaerobic threshold was identified in 94% of patients. At anaerobic threshold, VO~2~ was 0.80 ± 0.29 L/min (10.2 ± 3.2 mL/kg/min), HR was 90 ± 16 beats/min, and end‐tidal pCO~2~ was 35.1 ± 4.1 mmHg. At peak exercise, VO~2~ was 1.2 ± 0.4 L/min corresponding to 15.5 ± 4.7 mL/kg/min and to 61.8 ± 18.4% of the predicted value; HR was 111 ± 22 beats/min; and oxygen pulse was 11.4 ± 5.7 mL/min. The slopes of VE/VCO~2~ and VO~2~/work relationship were 31.1 ± 7.1 and 10.8 ± 4.6 L/min/W, respectively.

Patients were grouped according to the reason (muscular fatigue or dyspnoea) that led them to terminate the procedure (*Table* [1](#ehf212207-tbl-0001){ref-type="table"}). No difference was observed in terms of all analysed parameters derived from CPET and CPET‐CO (*Table* [2](#ehf212207-tbl-0002){ref-type="table"}). Patients\' data were included in the MECKI score dataset.[22](#ehf212207-bib-0022){ref-type="ref"} Cardiovascular mortality was low at 1 year (only two cases in the muscular fatigue group), confirming that patients were in stable clinical condition and optimized drug treatment.

###### 

General characteristics of patients who interrupted exercise because of muscular fatigue and those who did because of dyspnoea

![](EHF2-5-115-g001){#nlm-graphic-1}

ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; BMI, body mass index; BNP, brain natriuretic peptide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LVeDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LVeSV, left ventricular end‐systolic volume; NYHA, New York Heart Association; PAPs, pulmonary artery systolic pressure.

Patients were grouped according to the reason (muscular fatigue or dyspnoea) that led them to terminate the procedure. No difference was observed in terms of all analysed parameters. Data are expressed as mean ± standard deviation or as median (25th--75th quartile).

###### 

Difference of exercise parameters between patients who interrupted exercise because of muscular fatigue and those who did because of dyspnoea

  Variables                          Muscular fatigue (*n* = 132)   Dyspnoea (*n* = 38)   *P* value
  ---------------------------------- ------------------------------ --------------------- -----------
  Ramp protocol                      10 (6--12)                     8 (6--10)             0.13
  Test length, min                   9.22 ± 1.72                    9.68 ± 1.80           0.19
  Achievement of AT, %               94                             95                    0.85
  VO~2~ at AT, L/min                 0.82 ± 0.29                    0.81 ± 0.30           0.91
  VO~2~ at AT, mL/kg/min             10.4 ± 3.2                     10.5 ± 3.3            0.59
  HR at AT, beats/min                89 ± 15.1                      93 ± 17               0.19
  Work at AT, W                      48.9 ± 21.7                    48.7 ± 24.8           0.98
  Peak VO~2~, L/min                  1.21 ± 0.43                    1.14 ± 0.41           0.38
  Peak VO~2~, mL/kg/min              15.49 ± 4.77                   15.35 ± 4.34          0.87
  Peak VO~2~, % of predicted         61.8 ± 18.6                    62.1 ± 19.7           0.88
  Peak HR, beats/min                 110 ± 22                       114 ± 22              0.30
  Peak HR, % of predicted            72 ± 13.4                      74.7 ± 14.2           0.28
  Work at peak, W                    84.5 ± 33.2                    79.6 ± 34.3           0.43
  Peak O~2~ pulse, mL/beat           11.8 ± 6.2                     10.2 ± 3              0.12
  VE/VCO~2~ slope                    31.2 ± 6.8                     30.6 ± 8.2            0.65
  Peak PetCO~2~, mmHg                32.4 ± 4.7                     31.3 ± 4.5            0.20
  *Y* intercept, L/min               3.73 ± 2.33                    4.11 ± 3.23           0.47
  VO~2~/work slope, L/min/W          10.6 ± 4.2                     11.4 ± 5.5            0.34
  Peak Vt, L                         1.7 ± 0.5                      1.7 ± 0.6             0.87
  Peak VE, L                         52.5 ± 16.7                    51.7 ± 15.5           0.81
  Breathing reserve, %               42.3 ± 15.3                    43 ± 15.8             0.83
  Respiratory rate, breath/min       31.4 ± 7.5                     31.1 ± 7.2            0.78
  RER                                1.14 ± 0.11                    1.14 ± 0.10           0.87
  Baseline CO, L/min                 3.26 ± 0.98                    3.12 ± 0.92           0.43
  Peak CO, L/min                     6.68 ± 2.51                    6.21 ± 2.55           0.32
  Peak CO, % of predicted            51.6 ± 14.7                    49.4 ± 16.9           0.44
  Baseline SV, L/min                 48.5 ± 15.1                    46.6 ± 14             0.48
  Peak SV, L/min                     64.5 ± 21.2                    58.3 ± 16.2           0.10
  Peak SV, % of predicted            78.2 ± 21.6                    74.5 ± 19.6           0.36
  Baseline ΔCO~2~(a‐v), mL/100 mL    9.87 ± 3.2                     10.1 ± 2.7            0.74
  Peak ΔCO~2~(a‐v), mL/100 mL        18.2 ± 3.8                     18.2 ± 3.6            0.98
  Peak ΔCO~2~(a‐v), % of predicted   120 ± 26.8                     123 ± 27.9            0.65

AT, anaerobic threshold; CO, cardiac output; HR, heart rate; Pet, pressure end‐tidal; RER, respiratory gas exchange ratio; SV, stroke volume; VE, minute ventilation; VE/VCO~2~, ventilatory efficiency; VO~2~, oxygen uptake; Vt, tidal volume; ΔCO~2~(a‐v), arterio‐venous oxygen difference.

Patients were grouped according to the reason (muscular fatigue or dyspnoea) that led them to terminate the procedure. No difference was observed in terms of all analysed parameters. Data are expressed as mean ± standard deviation or as median (25th--75th quartile).

Discussion {#ehf212207-sec-0010}
==========

The main finding of the present study is that 22% of patients ended the effort because of dyspnoea and 78% because of fatigue. Patients ending a maximal effort because of dyspnoea had the same peak VO~2~, peak HR, peak CO, ΔCO~2~(a‐v), and VE/VCO~2~ slope as those ending their exercise because of fatigue.

We analysed data of HF patients in stable clinical conditions who performed two CPETs and excluded those who performed only CPET‐CO or with a time lag between the two tests \>2 months. The first test was used to assess the metabolic parameters during exercise and the cause of exercise termination; the second one, CPET‐CO, to measure CO by IGR. We chose this dual investigational strategy to avoid any possible interference of the rebreathing manoeuvre with the exercise performance and the sensation of dyspnoea. Indeed, we feared that the rebreathing manoeuvre, which requires an inspiration followed by five regular breaths at a fixed rate (usually 30 breath/min at peak exercise), might generate dyspnoea and somehow affect exercise performance. As a matter of fact, exercise tolerance was the same at both tests.

The percent of HF patients referring dyspnoea as the cause of exercise limitation varies among studies.[6](#ehf212207-bib-0006){ref-type="ref"}, [9](#ehf212207-bib-0009){ref-type="ref"}, [23](#ehf212207-bib-0023){ref-type="ref"} In the present study, we observed that the first cause for self‐ending a maximal effort referred by patients with chronic HF is fatigue (78% of cases), and dyspnoea was reported in 22% of cases. It should be noticed that our patients belong to a cohort HF regularly followed up at our HF unit, who were all in stable clinical condition and on optimal treatment; and, consequently, fluid balance was likely optimal, and that almost all had had previous experience of CPET in our laboratory, likely reducing test‐induced anxiety, which is more likely associated with dyspnoea.

Patients referring dyspnoea as the cause of exercise termination showed, at peak exercise and at the anaerobic threshold, data similar to those recorded in patients who referred fatigue as the cause of exercise limitation. Also the VO~2~/work relationship, an index of the efficiency of O~2~ delivery to the periphery, was similar. This datum, combined with direct CO measurement and calculated ΔCO~2~(a‐v), reinforces the concept of a similar haemodynamic behaviour during exercise. Moreover, the symptom referred by the patients as the cause of exercise termination was unrelated to HF severity or characteristics as evaluated by NYHA class, LVEF, haemoglobin concentration, or peak VO~2~.

It is of note that neither resting spirometry nor ventilatory parameters during exercise were able to differentiate patients who stopped exercise because of dyspnoea from those who stopped because of fatigue. In particular, neither the VE/VCO~2~ slope, a parameter of ventilatory efficiency known to increase in case of pulmonary hypertension, nor the VE intercept of the VE/VCO~2~ relationship, which increases in case of respiratory co‐morbidities in HF patients, was different.[24](#ehf212207-bib-0024){ref-type="ref"} It is therefore likely that the different symptoms referred are related to the individually built central reconstruction of similar peripheral signals, making impossible for the patients to differentiate between dyspnoea and fatigue or between central and peripheral exercise ending causes.

A few study limitations should be acknowledged. First of all, we have not tested the repeatability of the symptom referred as the cause of exercise termination by the patients. Similarly, in the present setting of patients, repeatability of peak CO was not tested, albeit IGR precision and repeatability have been previously shown.[19](#ehf212207-bib-0019){ref-type="ref"}, [20](#ehf212207-bib-0020){ref-type="ref"}, [21](#ehf212207-bib-0021){ref-type="ref"} Finally neither a Borg dyspnoea scale nor Borg Rating of Perceived Exertion scale was obtained at the end of each CPET.

In conclusion, in chronic HF patients in stable clinical condition and on optimal treatment, fatigue and dyspnoea as causes of exercise termination during self‐interrupted CPET do not underscore different cardiorespiratory or haemodynamic patterns.
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